Biosimilar medicines

Options for local implementation

- Biosimilar medicines have the potential to offer the NHS considerable cost savings and widen the access to innovative medicines, therefore providing increased value for money. The NHS is currently engaged in many activities that have already provided greater access to biosimilars for people with serious conditions.

- If such plans are not already in place, organisations should develop and agree local policies to be aware when biosimilar medicines are coming to market and then support their managed introduction into care pathways. This should be done safely and effectively, taking into account relevant regulatory advice, national guidance, patient factors and cost.

- Review and, if appropriate, optimise prescribing of medicines for which biosimilar medicines exist to ensure it is in line with these policies.

- Ensure all biological medicines, including biosimilar medicines, are prescribed by brand name so that products cannot be automatically substituted at the point of dispensing. The choice of whether a patient receives a biosimilar or originator biological medicine rests with the responsible clinician in consultation with the patient.
Evidence context

The NHS England publication, *What is a biosimilar medicine?* states that a biosimilar medicine is a biological medicine which is highly similar to another biological medicine already licensed for use. It is a biological medicine which has been shown not to have any clinically meaningful differences from the originator biological medicine in terms of quality, safety and efficacy. The continuing development of biological medicines, including biosimilar medicines, creates increased choice for patients and clinicians, increased commercial competition and enhanced value propositions for individual medicines. Biosimilar medicines have the potential to offer the NHS considerable cost savings and widen the access to innovative medicines. NICE’s medicines evidence commentary on bioequivalence between biosimilar and reference tumour necrosis factor-alpha inhibitors discusses a systematic review which assessed the comparability of clinical efficacy, adverse effects, immunogenicity and pharmacokinetics of biosimilar tumour necrosis factor (TNF)-alpha inhibitors and their reference biological medicine. This systematic review provided further assurance about the safety, effectiveness and comparable immunogenicity of biosimilar medicines.

NICE position statement on evaluating biosimilars

NICE's position statement on evaluating biosimilar medicines was published in January 2015. This states that biosimilars notified to the NICE topic selection process for referral to the technology appraisal programme will usually be considered in the context of a multiple technology appraisal, in parallel with their reference products in the indication under consideration. The Department of Health has confirmed that a technology appraisal remit referred to NICE enables NICE to decide to apply the same remit, and the resulting guidance, to relevant licensed biosimilar products which subsequently appear on the market. In other circumstances, where it is considered a review of the evidence for a biosimilar medicine is necessary, NICE will consider producing an evidence summary.

Licensing and comparability

Biosimilar medicines introduced into the UK market are authorised by the European Medicines Agency (EMA). The EMA in conjunction with the European Commission has produced information on biosimilar medicines, including an information guide for healthcare professionals and a question and answers document for patients. Biological medicines such as monoclonal antibodies, growth hormone and insulin are produced in or derived from living systems. The size and complexity of biological medicines, as well as the way they are produced, may result in a degree of natural variability in molecules of the same active substance, particularly in different batches of the medicine. The active substance of a biosimilar and its reference medicine is essentially the same.
biological substance but, just like the reference medicine, the biosimilar has a degree of natural variability. When approved, this variability and any differences between the biosimilar and its reference medicine will have been shown not to be clinically meaningful, with no differences expected in safety or effectiveness. The EMA and European Commission information guide for healthcare professionals states that the evidence acquired over 10 years of clinical experience shows that biosimilars approved through the EMA can be used as safely and effectively in all their approved indications as other biological medicines.

In the development of a biosimilar, there is no requirement to demonstrate clinical benefit to patients, as this has been shown for the reference medicine. Instead, biosimilars undergo a comprehensive regulatory process which demands extensive comparability studies that demonstrate similarity to the reference medicine. The benefits and risks are then inferred from the similarity of the biosimilar medicine to the reference medicine in terms of quality, efficacy and safety. Biosimilar medicines are usually licensed for all the indications in the licence of the originator biological medicine, but this requires appropriate scientific justification on the basis of demonstrated or extrapolated equivalence. Extrapolation needs to be supported by all the scientific evidence generated in comparability studies (quality, non-clinical and clinical). Biosimilars are generally used at the same dose and route of administration as the biological reference medicine and have the same contraindications and warnings in their summaries of product characteristics. However, the ongoing safety of any biosimilar or originator biological medicine is monitored separately.

See the NHS publication [Answers to commonly asked questions about biosimilar versions of infliximab](https://www.nice.org.uk/guidance/tk78) and the NHS England publication, [What is a biosimilar medicine?](https://www.nice.org.uk/about-nice/news/an-introduction-to-biosimilar-medicines) for more details.

**Brand name prescribing and pharmacovigilance**

In the UK, the MHRA recommends that all biological medicines, including biosimilar medicines, are prescribed by brand name ([February 2008 edition of Drug Safety Update](https://www.mhra.gov.uk/Assets/Mhrafiles/Drugsafetyupdate/2008/feb08.pdf)). Because biosimilar and reference biological medicines that have the same international non-proprietary name (INN) are not presumed to be identical in the same way as generic non-biological medicines, brand name prescribing ensures that the intended product is received by the patient. It ensures that products cannot be automatically substituted at the point of dispensing. The choice of whether a patient receives a biosimilar or originator biological medicine rests with the responsible clinician in consultation with the patient.

Pharmacovigilance is important for biosimilar medicines and every biosimilar authorised by the EMA will have a risk management plan in place (details of which will be in the European Public
Assessment Report). Based on similarity being demonstrated with the reference medicine, the biosimilar can also refer to the safety experience gained with the reference medicine. As with all new medicines, biosimilars have a ‘black triangle’ in the first years after approval and any suspected adverse drug reactions should be reported through the Yellow Card Scheme (see the June 2009 edition of Drug Safety Update on the black triangle scheme for more information).

Patient registers are used to monitor for emerging safety and efficacy issues with biological medicines, and the MHRA supports the recording of brand names and batch numbers for traceability when reporting suspected adverse drug reactions (November 2012 edition of Drug Safety Update). The NHS Specialist Pharmacy Service has developed a validated tool to determine potential safety issues associated with new medicines, and these ‘in-use product safety assessment reports’ will be published for new biosimilar medicines as they become available. The in-use product safety assessment reports for the infliximab biosimilars, Inflectra and Remsima, the etanercept biosimilar, Benepali, and the rituximab biosimilars Truxima and Rixathon, state that brand name prescribing is vital if products are to be identified appropriately at the points of dispensing and administration. As with all biological medicines, for each patient, a traceable record of the brand, batch number, and presentation of the product used should be made. Reporting and monitoring of patients through clinical registries will enable collection of specific data on serious adverse events, and these mechanisms will act in addition to routine pharmacovigilance activities. Safe introduction and ongoing safe use of biosimilars requires practitioner, patient and manufacturer engagement with these processes.

The EMA and European Commission information guide for healthcare professionals states that safety of biosimilars is monitored through pharmacovigilance activities, in the same way as for any other medicine. There is no specific safety requirement applicable only to biosimilars because of their different development route. Also, over the last 10 years, the European monitoring system for safety concerns has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines.

Managing the introduction of biosimilar medicines

NHS England are undertaking a programme of work to improve clinician confidence and clarify understanding amongst decision makers, such as commissioners, clinicians, pharmacists and patients in their consideration of the appropriate use of biosimilar medicines. This includes the publication of What is a biosimilar medicine? and a collaborative work programme to improve education and understanding of both the theory and practical considerations related to biosimilar medicines. Biological medicines are currently the largest cost and cost growth areas in the NHS medicines budget. Using a new commissioning framework, NHS England aims to drive a step
change in the uptake of biosimilar medicines by clinical commissioning groups (CCGs), who commission hospital trusts to provide the treatment, and make sure patients are offered the choice of switching to a new product by their specialist hospital doctor. It is important that there is high quality advice and information that meets the needs of patients and clinicians who will be involved in the process of switching to a biosimilar medicine, and provides answers to their questions. For clinicians, this information will be housed by the Regional Medicines Optimisation Committee (RMOC), hosted by the NHS Specialist Pharmacy Service. For patients, it will be accessible via NHS Choices.

NHS England are working with NHS Clinical Commissioners, regional Medical Directors and Academic Health Science Networks to maximise the opportunities of a more competitive biological medicines market for the benefit of patients.

The NICE adoption resource introducing biosimilar versions of infliximab: Inflectra and Remsima, was produced to help manage the introduction of biosimilar medicines into care pathways safely and effectively. NHS organisations shared their learning and experiences of introducing biosimilar medicines and these are presented as a series of examples of current practice. They are not presented as best practice but as real-life examples of how NHS sites have planned and managed the introduction of biosimilars. Local organisations will need to assess the applicability of the learning from the examples of current practice, taking into consideration the time, resources and costs of an implementation programme.

The NHS staff involved in the production of the NICE adoption resource reported that the use of biosimilars can reduce costs, allowing more treatment with new medicines, as long as the appropriate follow-up and monitoring systems are in place to manage risk and patient needs and expectations. Particular tips for managing the introduction of biosimilar medicines included:

- Identify clinical and pharmacy champions to take the lead in introducing biosimilars.
- Consult all stakeholders (including patients) to ensure confidence in using biosimilars.
- Provide information about the EMA licensing process for biosimilars, extrapolation and equivalence, and the manufacturing process (including intra-product manufacturing changes for both biological medicines and their biosimilars).
- Identify the potential cost-saving and re-investment opportunities and explore gain-share agreements.
- Seek formal approval at the local formulary committee once there is clinical consensus to include biosimilars on the formulary.
• Collect baseline data and agree metrics to be collected during and after the introduction of biosimilars.

• Submit data to national audits and registries.

Additional biosimilar adoption resources are also available through the NHS Cancer Vanguard. This education and engagement programme aims to improve healthcare professionals’ understanding of biosimilars and help them to better inform patients about their use and assist in their timely introduction when appropriate. A process timeline for adoption has been developed with accompanying guidance, resources and template documents, including the Cancer Vanguard biosimilars position statement, to support the NHS to enhance biosimilar uptake.

NICE's medicines evidence commentary on biosimilar infliximab: a successful managed switch programme in people with inflammatory bowel disease discusses the outcomes of a managed programme of switching at Southampton General Hospital. All 143 people with inflammatory bowel disease cared for at the hospital were switched from originator infliximab (Remicade) to biosimilar infliximab (Inflectra). The investigators found that the switch was highly acceptable to patients, clinicians, commissioners and other stakeholders. There was no evidence of any difference in terms of laboratory parameters, adverse effects or drug persistence. The drug acquisition costs reduced by £40,000–60,000 per month, which allowed an investment in care for people with inflammatory bowel disease that may have contributed to the improvement seen in some patient-reported outcome measures.

Further evidence supporting a biosimilar switch programme is discussed in NICE's medicines evidence commentary on switching to biosimilar infliximab in people with stable disease. This commentary reviews a 52-week, Norwegian, double-blind randomised study (NOR-SWITCH) which examined whether switching from originator infliximab to an infliximab biosimilar was safe and effective in 482 people on stable treatment with infliximab originator for a range of diseases. Switching to the biosimilar was found to be non-inferior to continuing originator infliximab in terms of disease worsening. The frequency of adverse events was similar between groups.

A number of professional organisations have now published guidance or position statements supporting the managed introduction of biosimilars. These include the British Society of Gastroenterology guidance on the use of biosimilar infliximab CT-P13 in inflammatory bowel disease; the British Society of Rheumatology updated position statement on biosimilar medicines; the British Oncology Pharmacy Association guidance on the implementation of biosimilar monoclonal antibodies; and the European Association of Hospital Pharmacists position paper on biosimilar medicines.
NICE's evidence summary on the insulin glargine biosimilar (Abasaglar) is also available.

Prescribing data, metrics or supporting resources

Biosimilar versions of epoetin, filgrastim and somatropin have been available for some time. Biosimilar versions of infliximab (Inflectra, Remsima and Flixabi); etanercept (Benepali and Erelzi); rituximab (Rixathon and Truxima); and insulin glargine (Abasaglar) have been launched in the UK. Further biosimilar versions of adalimumab, bevacizumab, pegfilgrastim, and trastuzumab are expected to be available in the next few years.

Biosimilars have the potential to offer the NHS considerable cost savings, especially as biological medicines are often expensive and are often used to treat long-term conditions. The NHS England publication, What is a biosimilar medicine? states that biosimilar medicines are more challenging and expensive to develop than generic medicines. Whilst they cannot offer the same percentage price reductions as traditional generic medicines, nevertheless, there are significant savings associated with increased competition between biological medicines, including biosimilar medicines. Recent research has given clear evidence that the additional competition is bringing value and opportunity to widen access for patients in some circumstances. However, this research also demonstrates that biosimilar medicine uptake across Europe to date shows very different patterns, depending on the class of biological medicine and the procurement measures in place. Costs for both biosimilar and originator biological medicines may vary locally depending on local contractual arrangements, and Regional Pharmacy Procurement Specialists will be able to provide more details.

The selection of metrics to support key therapeutic topics is overseen by the NHS England Medicines Optimisation Intelligence Group, and work is ongoing in this area. At this point, the following metrics have been identified by this group to support this topic.

Prescribing metrics on biosimilars are included in the Medicines optimisation dashboard, which brings together a range of medicines-related metrics from across sectors. These are:

- Biosimilars: % of infliximab biosimilars uptake, which is the percentage of defined daily doses for the biosimilar versions of infliximab
- Biosimilars: % of etanercept biosimilars uptake, which is the percentage of defined daily doses for the biosimilar versions of etanercept.

There is an intention to include other biosimilar medicines in the medicines optimisation dashboard.
as they become available. The medicines optimisation dashboard helps NHS organisations to understand how well their local populations are being supported to optimise medicines use and inform local planning. The dashboard allows NHS organisations to highlight variation in local practice and provoke discussion on the appropriateness of local care. It is not intended as a performance measurement tool and there are no targets.

There are also prescribing metrics on biosimilar infliximab, etanercept and rituximab in the NHS Improvement Model Hospital portal (requires log in). These metrics form part of the Top 10 Medicines sub-compartment of the Hospital Pharmacy & Medicines Optimisation section of the Model Hospital. This system has evolved from the simple uptake of the biosimilars (which is still included) to provide a monetised target and delivery of savings made through the individual trusts current uptake of each product. The data are provided using the Define benchmarking tool which 95% of acute trusts in England have purchased licences for and provide data into. The metric uses the defined daily dosage (DDD) of the biosimilar product used in a month as the numerator and the total DDD of the originator and biosimilar product used as the denominator. The data are displayed as a time series to show improvement over time and usage against other trusts and the national median. Additionally, the average cost per DDD is used to calculate a target saving for each trust if they have switched to 80% uptake of the biosimilar. An annual and monthly financial target, with the percentage uptake and savings delivered is given, which forms part of a monthly updated integrated performance framework to show individual trust savings delivery.

Since launch, the uptake of biosimilar infliximab, etanercept and rituximab has been variable across the country, with early adopter sites rapidly achieving greater than 90% adoption whilst other sites have slower uptake. The rate of biosimilar diffusion is, however, increasing and plans are in development to prepare for the launch of biosimilar adalimumab to maximise day 1 uptake.

The Model Hospital continues to be developed to support the principles and objectives developed from the Carter Review, Operational productivity and performance in English NHS acute hospitals: unwarranted variations. In addition to a range of infrastructure and service delivery related metrics, a range of clinical and medicines-related metrics have been developed, with additional metrics being added. These are linked to national commissioning and medicines optimisation developments. The Top 10 medicines are a key element of the Medicines Value Programme across NHS England & NHS Improvement as identified within the next steps on the Five Year Forward View.

One of the Hospital Medicines Optimisation Commissioning for Quality and Innovation (CQUIN) scheme priority areas for implementation is faster adoption of best value medicines with a particular focus on the uptake of best value generics, biologics and commercial medicines unit
frameworks as they become available. See [NHS England 2017 – 2019 Prescribed Services CQUIN Schemes](#) for more details. In order to allow NHS England to continue to invest in new developments there are requirements for all hospitals to use more cost-effective generic and biosimilar products where these are available and in line with product licences.

## Update information

**February 2018**: This topic was retained for the 2018 update of medicines optimisation: key therapeutic topics. The evidence context has been updated in the light of new guidance and important new evidence.

**January 2017**: This topic was retained for the 2017 update of medicines optimisation: key therapeutic topics. The evidence context has been updated in the light of new guidance and important new evidence.

## About this key therapeutic topic

This document summarises the evidence base on this key therapeutic topic which has been identified to support medicines optimisation. **It is not formal NICE guidance.**

For information about the process used to develop the key therapeutic topics, see the [integrated process statement](#).

ISBN: 978-1-4731-1669-6